Keymed Biosciences
Keymed Biosciences, a prominent player in the biotechnology sector, is headquartered in China (CN) and operates extensively across various regions. Founded in 2018, the company has rapidly established itself in the fields of drug discovery and development, focusing on innovative therapies for cancer and autoimmune diseases. Keymed Biosciences is renowned for its cutting-edge monoclonal antibody products, which leverage advanced technologies to enhance efficacy and safety. The company’s commitment to research and development has led to significant milestones, including successful clinical trials that underscore its market position. With a strong emphasis on scientific excellence and patient-centric solutions, Keymed Biosciences continues to make strides in the biopharmaceutical landscape, aiming to address unmet medical needs globally.
DitchCarbon Score
How does Keymed Biosciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Keymed Biosciences's score of 7 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Keymed Biosciences's reported carbon emissions
In 2023, Keymed Biosciences reported total carbon emissions of approximately 9,615,530 kg CO2e, with Scope 1 emissions at about 53,370 kg CO2e and Scope 2 emissions contributing approximately 9,562,160 kg CO2e. This marks a significant increase from 2022, where total emissions were about 4,928,560 kg CO2e, with Scope 1 emissions at approximately 174,230 kg CO2e and Scope 2 emissions at about 4,754,330 kg CO2e. In 2021, the company recorded total emissions of around 3,660,100 kg CO2e, with Scope 1 emissions of about 46,930 kg CO2e and Scope 2 emissions at approximately 3,613,170 kg CO2e. Despite these figures, Keymed Biosciences has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented climate pledges or targets suggests that the company may be in the early stages of developing a comprehensive climate strategy. As the industry increasingly prioritises sustainability, Keymed's future commitments will be crucial in aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 46,930 | 000,000 | 00,000 |
| Scope 2 | 3,613,170 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Keymed Biosciences is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
